ARHGAP10 was not only downregulated in breast cancer but also in other cancers including bladder cancer, esophageal cancer, liver cancer, prostate adenocarcinoma, rectum adenocarcinoma, skin cutaneous melanoma, uterine carcinosarcoma according to GEPIA. Here, ARHGAP10 is linked to urinary bladder cancer.